Mozobil for Autologous Hematopoietic Stem Cell Transplantation

This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.

Trial Details

NCT ID
NCT07188090
Phase
PHASE2
Sponsor
Thomas Jefferson University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Plerixafor
  • Gcsf
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
  • Age ≥18 years
  • Undergoing autologous stem cell transplant for one of the following diagnoses:
  • Multiple myeloma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →